A nonpeptide opioid was found in toad skin and purified to homogeneity by using HPLC with electrochemical detection. A nonpeptide opioid also was detected in bovine brain and adrenals as well as rabbit and rat skin, by reversedphase HPLC following Sephadex G-15 column chromatography. The material in toad skin was identical to morphine by immunological, pharmacological, and physical chemical criteria.
50 toads (about 800 g) and left in 4 liters of 95% methanol/5% 0.01 M HCl at 4°C for 1 week. The extract then was centrifuged at 20,000 x g for 10 min, and the supernatant was evaporated to dryness. The residue was dissolved in a minimum volume of 1 M Tris HCl buffer (pH 8.6) saturated with NaCl, adjusted to pH 8.5, and then extracted into 5 volumes of 10% 1-butanol in chloroform. The organic phase then was back-extracted with 2 volumes of 0.01 M HCl (6) . The recovery of morphine or 125I-labeled morphine by these extraction procedures is 50-70%. The aqueous phase was evaporated to dryness, dissolved in 30 ml of 1 mM HCl, centrifuged at 25,000 x g for 30 min, and then applied to a Sephadex G-15 column (2.6 x 100 cm). The immunoreactive fractions were eluted with 0.1 M pyridine/acetic acid (pH 6.2), collected, evaporated, and dissolved in 2 ml of 1 mM HCl. An aliquot was chromatographed by reversed-phase HPLC, using an Alltech Model 42 system with a LiChrosorb RP-18 column RESULTS Toad skin contained the greatest concentration of morphine immunoreactivity of the tissues tested (Table 1) . Morphine immunoreactivity was also found in rabbit and rat skin and bovine adrenal. The concentrations in the adrenal cortex and *To whom reprint requests should be addressed.
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Neurobiology: Oka et al. medulla were not significantly different from one another. In contrast to bovine brain, from which three immunoreactive peaks were obtained by RP-18 chromatography (5), all other tissues examined gave only one immunoreactive peak. Of the three immunoreactive peaks from the RP-18 column, one had a mobility that was similar to that of morphine. However, we were unable to further characterize this peak because of the low concentrations found in brain tissue. Of the other two immunoreactive species, one had a greater affinity for brain ,u receptors than did morphine. Incubation of the immunoreactive species from these tissues with Pronase for 1 hr at 37°C or heating them at 95°C for 10 min did not cause a loss of binding activity to antibody or receptor.
Since toad skin had the highest concentration of immunoreactivity, it was used as the source for the nonpeptide Proc. Nad. Acad Sci. USA 82 (1985) 1853 opioid. The organic solvent extraction procedure was based on the properties of morphine and its related derivatives. This procedure was effective also in eliminating substances that interfere with the RIA. Fig. 1 shows the chromatogram from Sephadex G-15, with one major immunoreactive fraction. The arrow indicates where morphine elutes from the column. The immunoreactive fraction was subjected to RP-18 reversed-phase HPLC (Fig. 2 A and B; an arrow indicates the retention time of pure morphine under each of the two pH conditions). The immunoreactive peak from toad skin was chromatographically indistinguishable from morphine. The resulting immunoreactive fraction was chromatographed on a Whatman Partisil 10 SCX ion-exchange column. As shown in Fig. 2C , a sharp peak was electrochemically detected that coincided with the immunoreactivity. The immunoreactive fraction was collected and rechromatographed under the same conditions; again, a single sharp peak was observed by electrochemical detection (Fig. 2D) .
Hydrodynamic voltammograms were obtained using HPLC/electrochemical detection. The nonpeptide opioid and morphine each were chromatographed on a Whatman Partisil 10 SCX column at a flow rate of 1 ml/min, using 0.1 M pyridine/acetic acid (pH 4.7) as the mobile phase. At oxidation potential of 0.5-0.9 V, the hydrodynamic voltammogram of the nonpeptide opioid is identical to that of morphine (Fig. 3 ).
To assist further in the identification of the morphine-like immunoreactivity, we developed mouse monoclonal antibodies to two immunogens, 3-carboxymethylmorphine and N-carboxymethylnormorphine. These monoclonal antibodies recognize different epitopes of morphine (unpublished results). Three different hybridoma clones were selected to study the cross-reactivity of the purified nonpeptide opioid. The IC50 values of the nonpeptide opioid to each monoclonal antibody were identical to those of morphine (Table 2) . Table 2 is a summary of the properties of the nonpeptide opioid as compared to morphine. There was no significant difference between the nonpeptide opioid and morphine in binding to either the polyclonal or monoclonal antibodies. This was also true when the comparison was made using the brain receptor assay. We also investigated the effect of sodi- Analysis by gas chromatography/mass spectrometry showed the same molecular ion for morphine and the nonpeptide opioid ( Table 2) .
The nonpeptide opioid also inhibited the guinea pig ileum contraction induced by electrical stimulation, at a concentration similar to that required for inhibition by morphine. At 8 nM, morphine inhibited the electrically stimulated contraction of the guinea pig ileum 30%; the extracted material likewise caused a 30% inhibition at 8 nM morphine immunoequivalents. This inhibition was reversed by naloxone. (1) (2) (3) . In the present study, we have isolated the compound from toad skin and have identified it as morphine. Although the compound was detected in other tissues, the concentrations were too low for characterization; however, the nonpeptide opioid in these tissues competes with morphine for binding to a polyclonal morphine antibody and to an opiate receptor. Toad skin had the greatest concentration of the nonpeptide opioid of all the tissues from various species analyzed and, therefore, was used for its isolation.
The original estimations of concentration of the morphinelike compound reported by Gintzler et al. (1) and later by Killian et al. (4) were much higher than that reported here. This discrepancy could be attributed to an over-estimation in the earlier studies because of some nonspecific binding in the RIA. Alternatively, since the isolation procedure has been modified, the morphine isolated could be different from the morphine-like compound previously reported. Immunoreactivity was also noted at the solvent front from the reversed-phase HPLC column. Since this fraction was not purified in these studies, it might account for the reduced estimation of morphine-like immunoreactivity.
One of the issues raised by Hazurn et al. (12) was that morphine can be derived from dietary sources. We did not determine whether morphine in the toad might be present due to ingestion. However, we could not detect any morphine in toad tissues other than skin; if the morphine were from an exogenous source, one would not expect it to be so limited in its localization. Since toad skin had relatively high concentrations of the nonpeptide morphine-like compound as compared to other tissues, we investigated rat and rabbit skin and found that concentrations of the morphine-like compound were higher than in other tissues. We tested rat and rabbit chow for the presence of morphine but were unable to detect any. Thus, we feel that the morphine we find in these tissues is not due to dietary sources. Two questions then have to be addressed. First, is the biosynthesis of morphine similar to that found in the poppy plant, Papaver somniferum? Second, what is the function of morphine in skin? Morphine causes dilatation of cutaneous blood vessels and, therefore, may be involved in regulating body temperature.
